A Phase 1 interventional study of LY2439821 and Placebo in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 8 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-05-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Eli Lilly and Company.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 29th largest by enrollment, is one of 5 that started in 2010, is one of 8 in phase 1, and was the 13th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company are open now, in 5 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Australia, China, Japan
Ages 18–55 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Germany
Ages 18–75 · Healthy volunteers
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 14 · Phase 3 11 · Phase 4 2
First in 2005; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 164 across the 35 interventional studies. Of the 33 that completed or were terminated, 30 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of multiple doses of LY2439821 in Japanese patients with rheumatoid arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
Drug: LY2439821
Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
Drug: LY2439821
Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
Drug: LY2439821
Placebo is administered subcutaneously in the same manner as active drug in each dose group
Drug: Placebo
Administered subcutaneously at 240 mg as a single loading dose followed by 120 mg every week
Drug: LY2439821
Administered subcutaneously
Administered subcutaneously
Number of Participants With Clinically Significant Effects
Clinically significant events were defined as serious and other non-serious adverse events. A summary of serious and all other non-serious adverse events is located in the Reported Adverse Event module.
Time frame: Baseline up to 26 weeks
Percentage Change From Baseline to 16 Week Endpoint in C-Reactive Protein
C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter.
Time frame: Baseline, 16 weeks
Percentage Change From Baseline to 16 Week Endpoint in Erythrocyte Sedimentation Rate (ESR)
Erythrocyte Sedimentation Rate (ESR) is a disease related biomarker and measured in millimeters per hour (mm/h).
Time frame: Baseline, 16 weeks
Change From Baseline to 26 Week Endpoint in Neutrophil Counts
Time frame: Baseline, 26 weeks
Change From Baseline to 26 Week Endpoint in Lymphocyte Counts
Time frame: Baseline, 26 weeks
Pharmacokinetics - Area Under the Concentration-time Curve (AUC) at Steady State (ss)
AUCτ,ss= area under the concentration versus time curve (τ) at steady state (ss)
Time frame: Week 10 pre-dose up to 2 weeks post-dose (Week 12)
Pharmacokinetics - Maximum Plasma Drug Concentration (Cmax) at Steady State (ss)
Cmax,ss = maximum observed drug concentration (Cmax) at steady state (ss)
Time frame: Week 10 pre-dose up to 2 weeks post-dose (Week 12)
Pharmacokinetics - Time of Maximum Observed Drug Concentration (Tmax) at Steady State (ss)
tmax,ss = time of maximum observed drug concentration (tmax) at steady state (ss)
Time frame: Week 10 pre-dose up to 2 weeks post-dose (Week 12)
| Milestone | 30 Milligram (mg) LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo |
|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 8 |
| Completed | 5 | 6 | 6 | 6 | 7 |
| Not completed | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Met predefined discontinuation criteria | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 |
Clinically significant events were defined as serious and other non-serious adverse events. A summary of serious and all other non-serious adverse events is located in the Reported Adverse Event module.
| participants | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo |
|---|---|---|---|---|---|
| Serious Adverse Events | 0 | 0 | 0 | 0 | 0 |
| Other Adverse Events | 4 | 5 | 3 | 3 | 6 |
C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter.
| percentage change in C-Reactive Protein | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo |
|---|---|---|---|---|---|
| Percentage Change From Baseline to 16 Week Endpoint in C-Reactive Protein | -88.75 (-98.6 to -66.7) | -73.81 (-98.8 to 180.0) | -17.04 (-48.4 to 150.0) | -95.47 (-99.3 to 100.0) | -8.07 (-82.8 to 186.2) |
Erythrocyte Sedimentation Rate (ESR) is a disease related biomarker and measured in millimeters per hour (mm/h).
| percentage change in ESR | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo |
|---|---|---|---|---|---|
| Percentage Change From Baseline to 16 Week Endpoint in Erythrocyte Sedimentation Rate (ESR) | -44.50 (-80.0 to -16.7) | -35.05 (-76.1 to 13.3) | -3.75 (-37.9 to 100.0) | -73.08 (-92.7 to -5.6) | -12.62 (-54.5 to 137.5) |
| 10^9 cells per liter (GI/L) | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline to 26 Week Endpoint in Neutrophil Counts | 0.681 (-5.77 to 5.84) | -0.559 (-2.62 to 5.62) | -0.170 (-0.87 to 2.72) | -2.677 (-2.87 to -0.70) | -0.641 (-2.94 to 2.29) |
| 10^9 cells per liter (GI/L) | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo |
|---|---|---|---|---|---|
| Change From Baseline to 26 Week Endpoint in Lymphocyte Counts | 0.189 (-1.19 to 1.23) | -0.011 (-0.54 to 1.25) | -0.184 (-0.37 to 0.09) | 0.138 (-0.15 to 0.65) | 0.085 (-0.56 to 0.24) |
AUCτ,ss= area under the concentration versus time curve (τ) at steady state (ss)
| micrograms•day per milliliter(μg•day/mL) | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 |
|---|---|---|---|---|
| Pharmacokinetics - Area Under the Concentration-time Curve (AUC) at Steady State (ss) | 77.2 ± 26 | 151 ± 44 | 437 ± 42 | 208 ± 48 |
Cmax,ss = maximum observed drug concentration (Cmax) at steady state (ss)
| micrograms per milliliter (μg/mL) | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 |
|---|---|---|---|---|
| Pharmacokinetics - Maximum Plasma Drug Concentration (Cmax) at Steady State (ss) | 7.05 ± 26 | 13.5 ± 43 | 39.3 ± 42 | 33.1 ± 56 |
tmax,ss = time of maximum observed drug concentration (tmax) at steady state (ss)
| days | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 |
|---|---|---|---|---|
| Pharmacokinetics - Time of Maximum Observed Drug Concentration (Tmax) at Steady State (ss) | 1.96 (1.91 to 7.00) | 1.93 (1.89 to 3.97) | 1.95 (1.88 to 2.02) | 3.89 (1.93 to 3.99) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 30 mg LY2439821 | — | 0/6 (0%) | 4/6 (66.7%) |
| 80 mg LY2439821 | — | 0/6 (0%) | 5/6 (83.3%) |
| 180 mg LY2439821 | — | 0/6 (0%) | 3/6 (50%) |
| 120 mg LY2439821 | — | 0/6 (0%) | 3/6 (50%) |
| Placebo | — | 0/8 (0%) | 6/8 (75%) |
| Event | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo |
|---|---|---|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 1/6 | 2/6 | 0/6 | 0/6 | 3/8 |
| NasopharyngitisInfections and infestations | 0/6 | 0/6 | 0/6 | 0/6 | 2/8 |
| Menopausal symptomsReproductive system and breast disorders | 1/4 | 0/6 | 0/3 | 0/4 | 0/5 |
| Eyelid oedemaEye disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/8 |
| Ocular hyperaemiaEye disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/8 |
| Dry mouthGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/8 |
| Mouth ulcerationGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/8 |
| NauseaGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/8 |
| Administration site reactionGeneral disorders | 0/6 | 1/6 | 0/6 | 1/6 | 0/8 |
| Feeling abnormalGeneral disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/8 |
| Age, Continuous(years) | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 53.0 ± 15.4 | 56.8 ± 7.2 | 61.7 ± 11.3 | 52.5 ± 14.0 | 60.1 ± 7.7 | 57.0 ± 11.2 |
| Sex: Female, Male(Participants) | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 6 | 3 | 4 | 5 | 22 |
| Male | 2 | 0 | 3 | 2 | 3 | 10 |
| Race/Ethnicity, Customized(participants) | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo | Total |
|---|---|---|---|---|---|---|
| Japanese | 6 | 6 | 6 | 6 | 8 | 32 |
| Region of Enrollment(participants) | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo | Total |
|---|---|---|---|---|---|---|
| Japan | 6 | 6 | 6 | 6 | 8 | 32 |
| C-Reactive Protein (CRP)(milligrams per liter (mg/L)) | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo | Total |
|---|---|---|---|---|---|---|
| Median | 7.950 (5.00 to 25.10) | 11.750 (2.00 to 50.10) | 3.500 (2.80 to 12.80) | 31.000 (9.30 to 95.20) | 5.650 (1.10 to 50.10) | 9.700 (1.10 to 95.20) |
| Erythrocyte Sedimentation Rate (ESR)(millimeters per hour (mm/h)) | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo | Total |
|---|---|---|---|---|---|---|
| Median | 28.0 (7 to 87) | 53.5 (23 to 107) | 26.0 (4 to 50) | 42.5 (22 to 81) | 25.5 (9 to 48) | 29.5 (4 to 107) |
| Neutrophils(10^9 cells per liter (GI/L)) | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo | Total |
|---|---|---|---|---|---|---|
| Median | 6.763 (3.13 to 7.67) | 4.293 (2.59 to 11.12) | 3.857 (2.59 to 5.26) | 6.056 (4.63 to 7.56) | 6.757 (4.14 to 8.97) | 5.261 (2.59 to 11.12) |
| Lymphocytes(10^9 cells per liter (GI/L)) | 30 mg LY2439821 | 80 mg LY2439821 | 180 mg LY2439821 | 120 mg LY2439821 | Placebo | Total |
|---|---|---|---|---|---|---|
| Median | 0.993 (0.42 to 2.62) | 1.156 (0.69 to 2.19) | 1.187 (0.88 to 2.01) | 1.379 (0.67 to 2.45) | 1.295 (1.06 to 2.29) | 1.275 (0.42 to 2.62) |
2 further baseline measures are reported on the registry.
The record gives a start of May 2010, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab